AI Article Synopsis
- Undernutrition and sarcopenia can worsen chemotherapy-related side effects and overall prognosis in cancer; this study focuses on the unclear impact of sarcopenia in advanced esophageal cancer patients.
- The research analyzed data from 31 esophageal cancer patients who received neo-adjuvant chemotherapy; it found that 51.6% had sarcopenia, but toxicity levels were similar in both sarcopenic and non-sarcopenic patients.
- Non-sarcopenic patients had better therapeutic responses to treatment (53.3% vs. 25.0%) and sarcopenia was identified as a significant predictor of poorer pathological response, indicating its importance
Article Abstract
Undernutrition and sarcopenia are associated with a higher incidence of chemotherapy-related toxicity and a poor prognosis in several kinds of cancer, but the impact of sarcopenia on the outcomes of chemotherapy for esophageal cancer remains unclear. Thus, the purpose of this retrospective study was to investigate whether sarcopenia affects the efficacy and toxicities of chemotherapy for advanced esophageal cancer patients. Data were collected from 31 esophageal cancer patients who underwent neo-adjuvant chemotherapy followed by surgery. Body composition was assessed at the start of chemotherapy by bioelectrical impedance analysis, and outcomes of chemotherapy were compared between sarcopenic and non-sarcopenic groups. Of the 31 patients, sarcopenia was observed in 16 (51.6%). The incidence of toxicities was not different between the two groups. However, as for pathologic response, a good therapeutic effect (Grade 2 or higher) was more common in the non-sarcopenic group than in the sarcopenic group (53.3% vs. 25.0%). Multivariate analysis showed that sarcopenia was an independent predictor of poor pathological response (odds ratio 8.02; P = 0.037). The results of this study suggest the potential utility of sarcopenia assessment in neoadjuvant patient selection strategies.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12032-018-1242-0 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
SUMO-Specific Peptidase 5 Promotes Oesophageal Squamous Cell Carcinoma Growth through the NF-κB- Axis.
Front Biosci (Landmark Ed)
January 2025
Department of Cardiothoracic Surgery, The Affiliated Jiangyin Hospital of Nantong University, 214400 Jiangyin, Jiangsu, China.
Background: This study investigates the role of small ubiquitin-like modifier (SUMO)-specific peptidase 5 (SENP5), a key regulator of SUMOylation, in esophageal squamous cell carcinoma (ESCC), a lethal disease, and its underlying molecular mechanisms.
Methods: Differentially expressed genes between ESCC mouse oesophageal cancer tissues and normal tissues were analysed via RNA-seq; among them, SENP5 expression was upregulated, and this gene was selected for further analysis. Immunohistochemistry and western blotting were then used to validate the increased protein level of SENP5 in both mouse and human ESCC samples.
Induction Radiochemotherapy for Esophageal Cancer: Long-Term Outcomes from a Single-Center Study.
J Clin Med
January 2025
2nd Department of General Surgery and Surgical Oncology, Medical University Hospital, 50-556 Wroclaw, Poland.
The management of esophageal cancer (EC) remains a significant clinical challenge, particularly in optimizing therapeutic strategies for different stages and subgroups. This study assessed the impact of preoperative radiochemotherapy (CRT) on clinical staging and identified subgroups for whom definitive CRT (dCRT) may provide a favorable alternative to surgery. Sixty-one patients with esophageal adenocarcinoma or squamous cell carcinoma were enrolled.
View Article and Find Full Text PDFGlobal Burden of Esophageal Cancer and Its Risk Factors: A Systematic Analysis of the Global Burden of Disease Study 2019.
Life (Basel)
December 2024
Department of Dermatovenerology, Faculty of Medical Sciences, University of Kragujevac, 34000 Kragujevac, Serbia.
Background: Esophageal cancer is a major public health issue, yet risk factors for its occurrence are still insufficiently known. This study aimed to estimate the global burden of esophageal cancer and its risk factors.
Methods: This ecological study presented the incidence, mortality, and Disability-Adjusted Life Years (DALYs) of esophageal cancer in the world.
Application of Spatial Transcriptomics in Digestive System Tumors.
Biomolecules
December 2024
Department of Gastric Surgery, Sun Yat-sen University Cancer Center, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Guangzhou 510060, China.
In the field of digestive system tumor research, spatial transcriptomics technologies are used to delve into the spatial structure and the spatial heterogeneity of tumors and to analyze the tumor microenvironment (TME) and the inter-cellular interactions within it by revealing gene expression in tumors. These technologies are also instrumental in the diagnosis, prognosis, and treatment of digestive system tumors. This review provides a concise introduction to spatial transcriptomics and summarizes recent advances, application prospects, and technical challenges of these technologies in digestive system tumor research.
View Article and Find Full Text PDFPLASMA: Partial LeAst Squares for Multiomics Analysis.
Cancers (Basel)
January 2025
Department of Biostatistics, Data Science, and Epidemiology, School of Public Health, Georgia Cancer Center at Augusta University, Augusta, GA 30912, USA.
: Recent growth in the number and applications of high-throughput "omics" technologies has created a need for better methods to integrate multiomics data. Much progress has been made in developing unsupervised methods, but supervised methods have lagged behind. : Here we present the first algorithm, PLASMA, that can learn to predict time-to-event outcomes from multiomics data sets, even when some samples have only been assayed on a subset of the omics data sets.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!